NSABP FR-2
NSABP FR-2
A Phase II Study to Assess the Activity of PD-L 1 Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Protocol Chair: Thomas George, MD
Protocol Officer: Gene Finley, MD
Patient Population:
Patients with microsatellite stable (MSS) stage II-IV rectal cancer following standard chemo-radiotherapy
Target Accrual: 41 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT03102407
A Phase II Study to Assess the Activity of PD-L 1 Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Protocol Chair: Thomas George, MD
Protocol Officer: Gene Finley, MD
Patient Population:
Patients with microsatellite stable (MSS) stage II-IV rectal cancer following standard chemo-radiotherapy
Target Accrual: 41 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT03102407